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Abstract
Conventional drug design embraces the ‘‘one gene, one drug, one disease’’ philosophy. Polypharmacology, which focuses
on multi-target drugs, has emerged as a new paradigm in drug discovery. The rational design of drugs that act via
polypharmacological mechanisms can produce compounds that exhibit increased therapeutic potency and against which
resistance is less likely to develop. Additionally, identifying multiple protein targets is also critical for side-effect prediction.
One third of potential therapeutic compounds fail in clinical trials or are later removed from the market due to unacceptable
side effects often caused by off-target binding. In the current work, we introduce a multidimensional strategy for the
identification of secondary targets of known small-molecule inhibitors in the absence of global structural and sequence
homology with the primary target protein. To demonstrate the utility of the strategy, we identify several targets of 4,5-
dihydroxy-3-(1-naphthyldiazenyl)-2,7-naphthalenedisulfonic acid, a known micromolar inhibitor of Trypanosoma brucei RNA
editing ligase 1. As it is capable of identifying potential secondary targets, the strategy described here may play a useful role
in future efforts to reduce drug side effects and/or to increase polypharmacology.
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Introduction
Researchers have traditionally focused in silico efforts on
designing inhibitors of specific protein targets, giving less attention
to the computational identification of unpredicted secondary
targets. This tendency is surprising given the frequency with which
secondary receptors are responsible for both detrimental and
beneficial pharmacological effects. The cost of developing a novel
therapeutic ranges from $500 million to $2 billion dollars [1].
Millions of dollars are typically invested to advance a compound
through clinical trials, but one third of these compounds fail or are
later removed from the market due to unacceptable, medically
harmful side effects [2] often caused by binding to off-target
receptors. The detrimental effects caused by drug binding to
unknown secondary targets can be financially and clinically
devastating.
In other cases, compound binding to multiple therapeutic
targets (polypharmacology) is beneficial. Conventional drug
discovery embraces the ‘‘one gene, one drug, one disease’’
philosophy; however, drugs that target only one protein are
susceptible to resistance, as a single amino-acid mutation in the
target active site often substantially reduces compound binding
affinity. Resistance to multi-target drugs, on the other hand,
requires simultaneous mutations in multiple protein targets.
Furthermore, drugs with polypharmacological mechanisms often
have greater therapeutic potency. Some serotonergic drugs, for
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the 5-HT3A ion channel to achieve their therapeutic benefits,
despite the fact that these two target proteins are not related by
sequence or structure [3].
Identifying secondary targets in neglected tropical diseases,
diseases for which drug development is neither profitable nor
prevalent, allows researchers and doctors to retool approved drugs
as novel treatments for the otherwise abandoned infections of the
developing world. For instance, eflornithine, initially developed as
an anti-cancer compound, was found to be a potent inhibitor of
Trypanosoma brucei ornithine decarboxylase and is now a critical
therapeutic in the fight against human African trypanosomiasis
[4]. Examples like these motivate the need to develop new tools
and algorithms to predict potential protein targets of candidate
compounds.
A barrier to the development of these tools is the frequent
absence of apparent evolutionary relationships among the multiple
protein targets of a given compound, requiring that any potential
method be capable of identifying target receptors independently of
global sequence or structural homology. One approach is chemo-
centric [5]; similar ligands are more likely to have similar
properties and therefore often bind proteins with similar active
sites. A number of studies have successfully identified secondary
receptors by comparing their known small-molecule ligands [3,6–
8], leading to probabilistic models that can in some cases
successfully predict polypharmacology. Despite these successes,
however, chemo-centric approaches have their limitations.
Chemically similar small molecules do not always inhibit proteins
with similar active sites; indeed, even small changes in the
chemical structures of some small-molecule inhibitors can
drastically alter binding affinity [3] and the broad profile of
binding to pharmacological targets.
A second approach is protein-centric. As the evolutionary
relationships between secondary targets are not always apparent
[3], receptor active-site geometries and pharmacophores must be
compared directly, independently of global sequence or structural
homology. Geometric constraints have been used extensively to
identify binding sites and to assess binding-site similarity [9–16].
Of these methods, the sequence order independent profile-profile
alignment (SOIPPA) algorithm is largely insensitive to both
conformational changes in protein structure as well as the
uncertainty inherent in homology models and low-resolution
structures [17].
In the current work, we present a novel multidimensional
strategy to identify the multiple protein receptors of a given
compound that incorporates three levels of information: sequence-
based homology clustering, the SOIPPA algorithm in conjunction
with a geometric-potential metric [17–19], and in silico ligand
docking. To demonstrate the utility of the strategy, we identify
several human and pathogen secondary targets of compound 1
(NSC-45208), 4,5-dihydroxy-3-(1-naphthyldiazenyl)-2,7-naphtha-
lenedisulfonic acid, a recently discovered micromolar inhibitor of
T. brucei RNA editing ligase 1 (TbREL1) [20]. TbREL1 is a
confirmed drug target in T. brucei, the causative agent of human
African trypanosomiasis, a disease for which drug development
has been largely neglected [21].
Results
Predicted Secondary Targets
Sequence homology clustering was used to identify 12,646
protein-chain clusters from among the 110,000 protein chains
present in the Protein Data Bank (PDB) as of late 2007 (Figure 1A,
B). A representative protein chain was chosen from each cluster,
creating a smaller set of chains called the PDB30 (Figure 1C). The
SOIPPA algorithm in conjunction with a geometric-potential
metric [17–19] revealed that the active sites of 12,428 of the
representative PDB30 protein chains (98.3%) were dissimilar to
that of TbREL1 (p.0.05), the known target. After discarding these
dissimilar protein chains, 218 representative PDB30 chains
remained (Figure 1D). The remaining PDB30 proteins and the
clusters they represented were merged into a single list containing
2,897 chains, a list enriched with possible secondary targets
(Figure 1E). By considering only proteins from human or known
human-pathogen species and eliminating PDBs with formatting
errors, the number of chains was reduced from 2,897 to 645
Figure 1. The strategy workflow. Circles and squares represent
protein chains. Homologous chains share the same color. From each
group of homologous chains, one is selected as representative and is
shown as a square. (A) As the PDB has approximately 110,000 protein
chains, identifying secondary targets directly is computationally
intractable. (B) To reduce the number of chains, all chains are grouped
by sequence homology into 12,646 clusters, and (C) a single
representative chain is selected from each cluster. The set of all
representative chains is called the PDB30. (D) SOIPPA is used to
eliminate all protein chains in the PDB30 with active sites that are
dissimilar to that of the primary target, TbREL1. Only 218 chains remain.
(E) A new set of 645 protein-chain structures called the PDBr is created
by taking the union of all those clusters whose representative PDB30
protein chains have active sites that are not dissimilar to that of TbREL1.
(F) Redundant chains are ignored; compound 1 is docked into the
remaining 87 protein chains. Chains are ranked by their corresponding
docking scores.
doi:10.1371/journal.pcbi.1000648.g001
Author Summary
Proteins play a critical role in human disease; bacteria,
viruses, and parasites have unique proteins that can
interfere with human health, and dysfunctional human
proteins can likewise lead to illness. In order to find cures,
scientists often try to identify small molecules (drugs) that
can inhibit disease-causing proteins. The goal is to identify
a molecule that can fit snugly into the pockets and
grooves, or ‘‘active sites,’’ on the protein’s surface.
Unfortunately, drugs that inhibit a single disease-causing
protein are problematic. A single protein can evolve to
evade drug action. Additionally, when only one protein is
targeted, drug potency is often diminished. Single drugs
that simultaneously target multiple disease-causing pro-
teins are much more effective. On the other hand, if
scientists are not careful, the drugs they design might
inhibit essential human proteins in addition to inhibiting
their intended targets, leading to unexpected side effects.
In our current work, we have developed a computer-based
procedure that can be used to identify proteins with
similar active sites. Once unexpected protein targets have
been identified, scientists can modify drugs under
development in order to increase the simultaneous
inhibition of multiple disease-causing proteins while
avoiding potential side effects by decreasing the inhibition
of useful human proteins.
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PLoS Computational Biology | www.ploscompbiol.org 2 January 2010 | Volume 6 | Issue 1 | e1000648(22.3%). This new list of protein chains was called the PDBr
(PDBreduced).
Compound 1, a known inhibitor of the primary target,
TbREL1, was docked into each of the 645 potential secondary
targets of the PDBr with AutoDock 4.0 (Figure 1F). After docking,
both protein chains of unknown function and chains belonging to
proteins with duplicate names were deleted without regard for
species. This pruning produced a list of 87 non-redundant
predicted secondary targets. The docked pose of 1 into each of
these 87 predicted secondary targets was analyzed to confirm
binding to a pocket of known biochemical or pharmacological
activity. In two instances, SITE data was included in the published
PDB file, allowing us to identify one active-site and one off-site
docking. In 25 instances, the docked ligand bound at the same
location as a co-crystallized ligand, typically superimposed on top
of it. Homology modeling revealed that an additional nine docked
ligands bound at active sites of known biochemical or pharma-
cological activity, while 34 bound at alternate sites on the receptor.
Though these alternate sites may be involved in allosteric
regulation of protein function, we chose not to pursue them
further. In all, the list of 87 protein chains contained 35 chains
whose known active sites contained docked ligands, 35 chains
whose alternate sites contained docked ligands, and 17 chains that
could not be classified (Text S1).
Experimental Validation of Predicted Secondary Targets
The predicted secondary targets that gave the best docking
scores, H. sapiens mitochondrial 2-enoyl thioester reductase
(HsETR1), T. brucei UDP-galactose 49 epimerase (TbGalE), H.
sapiens phosphodiesterase 9A (HsPDE9A2), and Streptococcus
pneumoniae teichoic acid phosphorylcholine esterase (SpPce), were
subsequently tested experimentally.
Compound 1 inhibited HsETR1 with a measured IC50 of
approximately 33.5 mM and a Hill slope of 1.06. Neither the
FATCAT algorithm nor CLUSTALW2 judged HsETR1 to be
significantly homologous in sequence or structure to the primary
target, TbREL1 (p=0.754; identity=4%). In contrast, the
SOIPPA algorithm judged the active sites of these two proteins
to be significantly similar (p,1610
25) (Table 1). HsETR1
aggregates were not detected, as measured by both spectrometry
and centrifugation. A mixture of compound 1 and HsETR1 was
run through a gel filtration column, thereby removing any
unbound ligand. Spectroscopic analysis subsequently demonstrat-
ed that 1 was not covalently bound to HsETR1.
Compound 1 inhibited TbGalE with a measured IC50 of
0.760.2 mM and a Hill slope of 1.13+/20.36. Again, the
FATCAT algorithm did not judge the structure of TbGalE to be
significantly similar to that of the primary target, TbREL1
(p=0.627), and the CLUSTALW2 algorithm did not identify
significant sequence homology (identity=1%) (Table 2). TbGalE
inhibition was unaffected by the presence of detergent, and activity
could be restored by dialysis of the protein, demonstrating that the
TbGalE inhibition was not due to aggregation of the compound or
chemical modification of the protein.
Two of the predicted secondary targets, HsPDE9A2 and SpPce,
were uninhibited by 1 at 200 mM and 10 mM, respectively.
AutoDock predicted that 1 would bind HsPDE9A2 and SpPce
with 218.19 and 228.00 kcal/mol, respectively (Tables 1 and 2).
Discussion
In this work, we attempt to further the study of polypharma-
cological and side-effect prediction by presenting a multidimen-
sional strategy for identifying secondary targets of known enzyme
inhibitors in the absence of global structure and sequence
homology. To demonstrate the utility of the strategy, we identify
secondary targets of 1, a recently discovered inhibitor of TbREL1
[20] from T. brucei, the causative agent of African sleeping sickness.
TbREL1 plays a critical role in the editing of trypanosomatid
mitochondrial RNA transcripts and is required for the survival of
both the T. brucei insect and bloodstream forms [22,23].
Additionally, TbREL1 is a particularly attractive drug target
because there are no known close human homologs [20].
Compound 1 was chosen to illustrate how the current strategy
can be applied early in the drug-discovery process. The compound
inhibits a known drug target, satisfies Lipinski’s rule of five, and is
structurally similar to surinam, a drug currently approved for the
Table 1. Selected predicted secondary targets of compound 1 in humans.
Protein AD Score SOIPPA p-value Sequence Identity FATCAT p-value
Metabolism UDP-glucose 4-epimerase (1I3L:B) 211.22 3% 0.613
NAGK (2CH5:C) 210.75 3.45610
22 9% 0.351
acetyl-CoA carboxylase 2 (2HJW:A) 210.28 7.82610
23 5% 0.423
mitochondrial 2-enoyl thioester reductase
(1ZSY:A)
210.04 ,1610
25 4% 0.754
tubby isoform A (1S31:A) 29.17 6% 0.615
DNA synthesis, repair, replication DNA ligase I (1X9N:A, residues 535–751) 29.70 ,1610
25 5% 3.82610
23
3-methyl-adenine DNA glycosylase (1EWN:A) 29.09 1.18610
22 10% 0.800
thymidylate synthase (1I00:A) 28.50 3% 0.237
Amino acid synthesis pyrroline-5-carboxylate reductase 1 (2GR9:B) 210.49 4.28610
22 1% 0.702
Blood clotting fibrinogen (1FZE:B) 29.53 4% 0.626
Vision tubby related 1 (2FIM:B) 210.21 2.60610
22 3% 0.637
Nuclear transport snurportin-1 (1XK5:A) 210.10 ,1610
25 4% 6.07610
24
Human secondary targets are involved in metabolism; polynucleotide synthesis, repair, and replication; amino acid synthesis; blood clotting; vision; and nuclear
transport. ‘‘AD score’’ refers to the AutoDock-predicted energy of binding to 1; ‘‘SOIPPA p-value’’ refers to the similarity between the secondary-target and TbREL1 active
sites; ‘‘sequence identity’’ refers to the percent amino-acid identity with TbREL1 as computed by the CLUSTALW2 algorithm; and ‘‘FATCAT p-value’’ refers to the
structural similarity between the secondary target and TbREL1. Protein sequences were extracted from PDB seqres headers.
doi:10.1371/journal.pcbi.1000648.t001
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drug like. Compound 1 has not yet been optimized to bind
TbREL1 in the nanomolar regime, however, and does contain
some undesirable functional groups, and so is still very much
under development. By incorporating the identification of
secondary targets early in the drug-design process, we hope to
eventually make modifications to compound 1 that will increase
the binding affinity to the primary target while decreasing binding
to undesirable secondary targets.
Human Secondary Targets
Of the 35 predicted secondary targets of compound 1 identified,
twelve were human proteins. Potential side effects of 1 can be
predicted by considering the physiological role of these targets. For
instance, a number of the predicted secondary human targets
regulate metabolism, including the experimentally confirmed
secondary target HsETR1. Neither FATCAT nor CLUSTALW2
judged HsETR1to be homologous to the primary target, TbREL1
(Table 1). The current strategy, which is not dependent on
sequence or global structural homology, was able to identify this
secondary target where identification by homology would have
failed. HsETR1 is thought to be essential for fatty acid synthesis
(FAS) type II [24]. In the process of optimizing 1 to make it more
druglike, modifications that reduce binding to human HsETR1
may diminish unforeseen side effects. Interestingly, AutoDock
predicted that 1 partially occupies a co-factor (NADPH) binding
site, suggesting that the compound may function as a competitive
inhibitor for NADPH (Figure S1A).
H. sapiens UDP-galactose 4-epimerase (HsGalE), a second
protein involved in human metabolism, was also identified as a
potential secondary target. Though HsGalE shares little homology
with the primary target, TbREL1 (FATCAT p-value: 0.610;
CLUSTALW2 identity: 2%), it is highly homologous with TbGalE
(FATPAT p-value: 0.00; CLUSTALW2 identity: 37%; Figure
S2A), which we show to be a secondary target of 1 (IC50:
0.760.2 mM). Mutations in the HsGalE gene cause type 3
galactosemia in humans. As toxic levels of galactose build up in
patients’ blood, vomiting, hepatomegaly, jaundice, renal failure,
and cataracts typically follow [25]. Chronic administration of 1 is
thus ill advised, though short-term treatment may be acceptable if
patients avoid dairy and other sources of galactose.
In addition to metabolism, a number of the predicted human
secondary targets are involved in polynucleotide synthesis, repair,
and replication. H. sapiens DNA ligase I (HsLigI), a protein that
belongs to the same enzyme superfamily as TbREL1, is one
notable example. HsLigI catalyzes the ultimate, essential step in
DNA replication, repair, and recombination [26]. Studies have
demonstrated that HsLigI is defective in at least one representative
lymphoid cell line of Bloom’s syndrome origin [27], and a mouse
model with a mutant HsLigI allele exhibits an increased incidence
of spontaneous cancer [28].
Though not tested explicitly, additional evidence does suggest
that 1 binds HsLigI. First, 1 is known to inhibit H. sapiens DNA
ligase IIIb (HsLigIIIb;I C 50: 27.4966.40 mM) [20], a HsLigI
homolog (Table 3). Second, the FATCAT algorithm [29] judged
the structure of HsLigI to be significantly similar to that of the
primary target, TbREL1, and the SOIPPA algorithm judged the
active sites of these two proteins to be similar (Table 1). Finally, the
AutoDock-predicted binding energy of 1 to HsLigI was
29.70 kcal/mol (Table 1).
Secondary Targets in Bacterial and Parasitic Pathogens
Of the 35 predicted secondary targets identified, 23 belonged to
bacterial and parasitic species. Among these predicted pathogenic
secondary targets, enzymatic assays demonstrated that 1 inhibits
TbGalE [30] (Table 2) with high nanomolar affinity. Interestingly,
the FATCAT algorithm did not judge the structure of TbGalE to
be significantly similar to that of the primary target, TbREL1
(Table 2), nor did CLUSTALW2 suggest sequence homology
(identity=1%). Thus, had we attempted to identify secondary
targets by protein sequence or structural homology alone, TbGalE
Table 2. Selected predicted secondary targets of compound 1 in pathogens.
Protein Species AD Score SOIPPA p-value Sequence Identity FATCAT p-value
probable ATP-dependent DNA ligase (2FAO:A) Pseudomonas aeruginosa 210.57 1.34610
22 5% 0.440
UDP-galactose 4-epimerase (1GY8:D) T. brucei 210.29 1% 0.622
dTDP-D-glucose 4,6-dehydratase (1KET:B) Streptococcus suis 29.55 5% 0.502
dihydrofolate reductase-thymidylate (1J3I:C) Plasmodium falciparum 29.53 1.34610
22 5% 0.428
DNA ligase, NAD-dependent (1TAE:B) E. faecalis v583 29.49 8% 3.56610
22
dTDP-D-glucose 4,6-dehydratase (1G1A:C) S. enterica 29.24 1% 0.529
adenine phosphoribosyltransferase (1MZV:A) Leishmania tarentolae 28.61 11% 0.649
UTP-gluc-1-P uridylyltransferase 2 (2OEG:A) Leishmania major 28.56 7.82610
23 8% 0.724
purine nucleoside phosphorylase (2B94:A) Plasmodium knowlesi 27.61 2% 0.650
DNA ligase (1ZAU:A) M. tuberculosis 26.75 4% 2.82610
22
‘‘AD score’’ refers to the AutoDock-predicted energy of binding to 1; ‘‘SOIPPA p-value’’ refers to the similarity between the secondary-target and TbREL1 active sites;
‘‘sequence identity’’ refers to the percent amino-acid identity with TbREL1 as computed by the CLUSTALW2 algorithm; and ‘‘FATCAT p-value’’ refers to the structural
similarity between the secondary target and TbREL1. Protein sequences were extracted from PDB seqres headers.
doi:10.1371/journal.pcbi.1000648.t002
Table 3. Global sequence and structural homology between
HsLigI, residues 535 to 751, and three other selected DNA
ligases.
Identity Similarity FATCAT p value
HsLigIIIb 31% -
E. faecalis v583 NAD-dependent
DNA ligase
4% 2.36610
27
M. tuberculosis DNA ligase 4% 1.07610
26
doi:10.1371/journal.pcbi.1000648.t003
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power of the current strategy.
Like TbREL1, TbGalE is essential for T. brucei survival [31].
Thus, 1 inhibits two essential T. brucei enzymes, an example of
potential polypharmacology. In the process of optimizing 1 to
make it more druglike, modifications that increase binding to both
TbREL1 and TbGalE would likely improve drug efficacy and
decrease the chances of resistance through mutation. Interestingly,
AutoDock again predicted that 1 would bind partially in the
TbGalE NAD
+ pocket, suggesting that the compound may be a
competitive inhibitor for NAD
+ rather than UDP-galactose
(Figure S1B).
Though not tested explicitly, another predicted secondary target
in pathogens, Salmonella enterica dTDP-D-glucose 4,6 dehydratase
(SeRmlB), shares sequence and structural homology with TbGalE
and may also bind 1 (Table 2, Figure S2A). The FATCAT
algorithm judged SeRmlB to be significantly structurally similar to
TbGalE (p value=0.00), and CLUSTALW2 identified some
sequence homology (identity=21%). Additionally, AutoDock
predicted that SeRmlB would bind 1 with relatively high affinity
(Table 2).
SeRmlB is the second enzyme in the dTDP-L-rhamnose
biosynthetic pathway; L-rhamnose is part of the LPS endotoxin
(the O antigen) in many serotypes and serovars of Gram-negative
bacteria. As L-rhamnose is common in the cell walls and envelopes
of some pathogenic bacteria but absent in humans, SeRmlB is
thought to be a potential drug target [32]. These findings support
the hypothesis that compounds similar to 1 may have anti-
bacterial properties.
Aside from inhibiting an essential protein in the bacterial
dTDP-L-rhamnose biosynthetic pathway, the current strategy also
identified two bacterial DNA ligases as potential secondary targets.
Enterococcus faecalis v583 NAD-dependent DNA ligase (Ef ligase)
and Mycobacterium tuberculosis DNA ligase (Mt ligase) are structurally
homologous to HsLigI (Table 3, Figure S2B). Human DNA ligases
require ATP as a co-factor, but bacterial ligases require NAD
+
[33]. Because of this important biochemical difference, bacterial
ligases are thought to be good drug targets.
Method Limitations
A limitation of the current method is the prediction of false
positives. Two of the predicted secondary targets, SpPce and
HsPDE9A2,wereuninhibitedby1.Closerinspection ofthedocking
results revealed electrostatic energy components of 230.89 kcal/
mol and 212.29 kcal/mol, respectively. In both cases, the partial
charges of several active-site metal cations had been manually set to
the correspondingformal charge.Subsequent analysis of the docked
poses revealed that for both receptors, one of the sulfonate groups of
1 was juxtaposed against these highly charged metal cations (Figure
S3). Clearly, a more careful treatment of the electrostatic
interactions that accounts for electron polarization is warranted
when docking into active sites that include metal ions.
An additional limitation of the current method is its dependence
on sequence-homology clustering. Because of computational
limitations, the number of potential secondary targets analyzed
with SOIPPA had to be reduced; consequently, rather than
analyzing all protein chains in the PDB, representative chains were
selected from clusters of homologous proteins based on the
supposition that sequence-homologous proteins would likely have
similar active sites. This supposition, however, is hardly a universal
truth. Through convergent evolution, two proteins with very
different primary sequences may have evolved to bind similar
ligands, and so may have similar active sites despite a lack of
sequence homology.
Fortunately, recent advances in the SOIPPA algorithm now
make sequence-homology clustering unnecessary. The version of
SOIPPA used in the current study estimated the statistical
significance of each active-site comparison using a non-parametric
statistics method that required at least several hundred additional
comparisons to derive a background distribution. Recently, an
extreme-value distribution model has been developed to compute
the statistical significance of SOIPPA scores [34]; this model
improves the speed of the algorithm by at least two orders of
multitude, so that each active-site comparison can be performed in
mere seconds. Ligand binding-site similarity searches can now be
performed on a genome-wide scale without the need for sequence-
homology clustering [34,35]. The new statistical model has been
implemented in SMAP v2.0, available at http://funsite.sdsc.edu.
The manual verification of predicted compound binding to
active sites of known biochemical or pharmacological activity also
presented a limiting challenge. This step was very time consuming;
had multiple compounds been tested, manual verification of all
docked poses may have been impossible. To automate the process,
active-site binding can be confirmed in many cases based on the
proximity of the docked ligand to known catalytic residues
annotated in the Catalytic Site Atlas [36] or to active-site residues
specified in the site records of the PDB. Additionally, the SOIPPA
implementation in SMAP v2.0, not available until recently,
suggests an initial ligand binding pose for each predicted
secondary target. Docked poses could be compared to this initial
suggestion using an automated script and rejected in the absence
of proximity.
Accounting for Possible Promiscuous Binding
As experimental validation has confirmed that 1 inhibits
multiple protein targets, the possibility of nonspecific, promiscuous
binding must be eliminated. Previous work has demonstrated that
compound 1 inhibition of several ATP-dependent proteins
depends on the degree of homology with the primary target,
TbREL1, suggesting that binding occurs via a specific rather than
promiscuous mechanism [20]. Additionally, the lack of SpPce or
HsPDE9A2 inhibition further suggests that indiscriminant inhibi-
tion is unlikely.
Promiscuous inhibition can occur when a compound forms
colloidal aggregates that inhibit indiscriminately. In one recent
study, 95% of the inhibitors identified in a high-throughput screen
were subsequently found to inhibit via a nonspecific aggregation-
based mechanism [37]. In theory, the chances of aggregation are
reduced in the case of 1 because of its negative charge; individual
molecules should repel each other, preventing aggregation. To
confirm this theory, Amaro et. al assayed 1 against TbREL1 in the
presence of a non-ionic detergent as well as an additional protein
(BSA) known to prevent aggregation. The presence of the
detergent and the separate test with BSA did not significantly
influence TbREL1 inhibition, demonstrating that 1 does not
aggregate [20].
The current work likewise suggests no aggregation. The
presence of detergent had no effect on TbGalE inhibition.
Additionally, no HsETR1 aggregation was observed, as measured
by both spectrometry and centrifugation (see the Text S1). The
Hill slopes corresponding to the inhibition of HsETR1 and
TbGalE were 1.06 and 1.13, respectively. As these slopes are
approximately equal to one, the inhibition of these two proteins
likely occurs via ligand binding to a single site, as predicted. One
recent study suggested that aggregation-based inhibition typically
produces Hill slopes that are much steeper, with average values of
about 2.2 [37].
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chemically modify the proteins they inhibit. Several experiments
were performed in order to rule out chemical modification. To test
for chemical modification of TbGalE, TbGalE was incubated with
1, and subsequent dialysis was used to remove any unbound
ligand. TbGalE activity was unaffected following dialysis, as
compared to treatment with DMSO alone. Had 1 been covalently
linked to TbGalE, the compound would not have been washed
away, and the enzyme would have shown little activity.
To test for chemical modification of HsETR1, a mixture of
compound 1 and HsETR1 was run through a gel filtration
column, which likewise removed any unbound ligand. The
absorption spectrum of the fraction containing HsETR1 was
subsequently analyzed and did not demonstrate the peaks
characteristic of 1 at 530 nm and 320 nm, likewise demonstrating
that 1 was not covalently bound to HsETR1.
A Cursory Chemo-Centric Analysis
A number of the predicted secondary targets identified belong
to the same or similar biochemical pathways (i.e. metabolic
pathways; DNA synthesis, repair, and replication pathways; and
DNA ligase pathways) (Table 1). This result is encouraging, as
proteins of the same pathway often act on similar substrates and so
have similar active sites. A cursory chemo-centric look at the
native substrates of the identified secondary targets in many
instances corroborates our findings. For instance, the human
proteins HsLigI, 3-methyl-adenine DNA glycosylase, and thymi-
dylate synthase, all involved in DNA synthesis, repair, and
replication, were identified as potential target receptors. HsLigI
is a TbREL1 homolog (Table 1) that ligates DNA in a way
analogous to TbREL1 dsRNA ligation. In contrast, 3-methyl-
adenine DNA glycosylase is not a TbREL1 homolog (Table 1), but
an examination of its structure nevertheless reveals that it also
binds DNA. One of the nucleotides of the bound DNA, an
alkylated base generated endogenously by lipid peroxidation,
protrudes into a deep binding pocket in a way analogous to
TbREL1-ATP binding [38]. Thymidylate synthase, another
predicted secondary target involved in nucleotide synthesis, does
not bind double-stranded nucleic acid, but rather binds deoxyur-
idine monophosphate, a compound with a nucleotide-ribose-
phosphate substructure like that of ATP, a known substrate of the
primary target, TbREL1.
Notably, two experimentally validated secondary targets contain
NAD
+ or NADPH co-factors, and in both cases 1 is predicted to
bind at least partially in one of the co-factor binding pockets.
Similar to ATP, NAD
+ and NADPH both contain adenine-ribose-
biphosphate substructures. Of the 23 proteins listed in Tables 1
and 2, eight contain NAD
+-like co-factors. We expect that there
are even more true positives among the predicted secondary
targets; to this end, we provide the entire list of predicted targets in
Text S1.
Traditionally, researchers have devoted their computational
efforts to designing inhibitors of specific protein targets while
paying less attention to the in silico prediction of secondary targets.
Because adverse side effects are often discovered late in the drug-
development process, often after the investment of many millions
of dollars, we recommend using the current strategy to help bad
drugs ‘‘fail early,’’ or, better yet, to guide the drug-discovery
process towards more selective inhibitors. Additionally, the current
methodology can help medicinal chemists overcome the conven-
tional ‘‘one gene, one drug, one disease’’ paradigm. The rational
design of drugs that act via polypharmacological mechanisms can
produce compounds that exhibit increased therapeutic potency
and against which resistance is less likely to develop.
Materials and Methods
Compound Purity
Compound 1 was provided by the NCI/DTP Open Chemical
Repository (http://dtp.cancer.gov). Compound identity was
confirmed by high-resolution mass spectrometry, and no impuri-
ties were detected by
1H-NMR.
Computational Methodology
The computational strategy presented here utilizes three distinct
components in order to identify secondary pharmacological targets.
1. Homology Clustering: Creating a Non-Redundant PDB
Representation
Identifying potential secondary targets from among the 110,000
protein chains deposited in the RCSB PDB [39] as of late 2007 was
judged computationally intractable. In order to reduce the number
of protein chains, redundancies in the RCSB PDB were eliminated
by clustering all protein chains by sequence using the NCBI blastclust
program, with a sequence identity threshold of 30% and an overlap
threshold of 0.9 (Figure 1A, B). A representative protein chain was
then chosen at random from each cluster, thus creating a smaller set
of chains called the PDB30 (Figure 1C).
2. SOIPPA: Identifying Active Sites Similar to that of the
Primary Target
In order to eliminate those members of the PDB30 whose active-
site alpha-carbon configurations were different enough from that of
the primary target, TbREL1, so as to likely preclude NSC4520
binding, we used the SOIPPA algorithm in conjunction with a
geometric potential [17–19], which computes general binding-site
similarity based on shape (alpha-carbon tessellation), physical
properties, and the evolutionary profiles of the active-site residues,
without regard for specific side-chain positions or global sequence or
structure (Figure 1D). Using SOIPPA and the geometric potential,
we eliminated all protein chains in the PDB30 with active sites that
weredissimilartothatoftheprimarytarget,TbREL1(p-value.0.05)
(Figure 1D). The p-value was calculated from a non-parametric
density function generated from 980 PDB chains with unique SCOP
folds [18]. To derive the background distribution, a Gaussian
function was placed at each observation. The mean of the Gaussian
of the observed binding-site similarity score and its variance were
fixed. The final probability density function was the sum of all these
Gaussian functions. The optimal bandwidth was estimated from the
data by using a least square cross-validation approach [40].
Each representative protein chain corresponded to a PDB
cluster containing multiple homologous chains. A new set of
protein-chain structures called the PDBr (PDBreduced) was created
by taking the union of all those clusters whose representative
PDB30 protein chains had active sites that were not dissimilar to
that of TbREL1 (p-value,0.05) (Figure 1E). By considering only
proteins from human or known human-pathogen species, the
number of chains was significantly reduced. An additional protein,
1GJJ, was eliminated because of apparent PDB formatting errors.
1S31 was retained despite having a malformed GLU residue (561)
to which Gasteiger partial charges could not be assigned.
3. In silico Docking
AutoDock 4.0 [41] was used to dock 1 into the protein chains of
the PDBr (Figure 1F). In previous work, AutoDock was validated
against TbREL1 [20]. To define the distinct docking grid
associated with each protein chain, SOIPPA was used to identify
the most probable active site, and the grid box was set to the
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SOIPPA-reported alignable alpha carbons. Additional details
regarding receptor and ligand preparation and grid and docking
parameters can be found in Text S1.
All dockings were sorted by the predicted binding energy of their
most-populated AutoDock clusters. After eliminating protein chains
ofunknownfunctionfromthelist,thedatawasgroupedaccordingto
species and protein, revealing significant redundancy in the PDBr.
We selected the ligand-protein pair from each group with the best
AutoDock score, producing a list of non-redundant ligand-protein
pairs, one corresponding to each protein/species group (Text S1).
For each of these ligand-protein pairs, we used one of several
methods to determine if AutoDock placed 1 in an active site of
known biochemical or pharmacological activity. First, SITE data
included in the published PDB file identified several active sites.
Second, co-crystallized ligands bound in native active sites were
examined. Finally, homology modeling was used to determine the
locations of active sites for the remaining protein chains, when
possible. A protein chain was considered to be a ‘‘hit’’ if 1 had a
high predicted energy of binding and if 1 was predicted to bind in
an identified active site of known biochemical or pharmacological
activity. A description of the assays used to experimentally validate
several of the predicted secondary targets is included in Text S1.
Supporting Information
Text S1 Text S1 contains details about the computational
methods employed and the assays used to confirm theoretical
results. It also contains expanded versions of Tables 1 and 2.
Found at: doi:10.1371/journal.pcbi.1000648.s001 (0.23 MB
DOC)
Figure S1 Possible binding of compound 1 in NAD+ and
NADPH pockets. In the case of two experimentally validated
secondary targets, AutoDock predicted that 1 would bind in a
NAD+ or NADPH pocket, suggesting that 1 may be a competitive
inhibitor for these co-factors. (a) HsETR1. The crystal structure
(PDB: 1ZSY) contained no NAD+ co-factor, so a related structure
(PDB: 1GUF) with co-crystallized NDP (NADPH dihydro-
nicotinamide-adenine-dinucleotide phosphate) was aligned to the
1ZSY structure using MultiSeq. The aligned NDP is shown in red.
The predicted binding pose of 1 is shown in green. (b) TbGalE.
The co-crystallized NAD+ co-factor is shown in red. The
predicted binding pose of 1 is shown in green.
Found at: doi:10.1371/journal.pcbi.1000648.s002 (3.98 MB TIF)
Figure S2 Unvalidated but likely secondary targets of compound
1. (a) The current strategy correctly identified TbGalE as a
secondary target of 1. Additionally, HsGalE and SeRmlB, both
TbGalE homologs, are also predicted to be off-target receptors.
SeRmlB and TbGalE were aligned to HsGalE using MultiSeq to
demonstrate structural similarity. Blue: TbGalE; Red: SeRmlB;
Green: HsGalE. (b) The current strategy identified a number of
DNA ligases as predicted secondary targets of 1. Three of these
DNA ligases are homologous with HsLigIIIb, an experimentally
validated secondary target. The structures of the three predicted
secondary targets were aligned using MultiSeq to demonstrate
structural similarity. Portions of some ligands were removed to
simplify visualization. The active site is shown with selected
protein residues to demonstrate active-site similarity. Blue: HsLigI;
Red: Ef ligase; Green: Mt ligase.
Found at: doi:10.1371/journal.pcbi.1000648.s003 (3.65 MB TIF)
Figure S3 False-positive predictions. Compound 1 is shown in
licorice, docked into each protein crystal structure. Magnesium
and zinc are shown in green and grey, respectively. In both cases,
one of the sulfonate groups of 1 is juxtaposed against multiple
metal cations, leading to an exaggerated estimate of the
electrostatic energy. (a) SpPce was predicted to bind 1 with
228.00 kcal/mol. (b) HsPDE9A2 was predicted to bind 1 with
218.19 kcal/mol.
Found at: doi:10.1371/journal.pcbi.1000648.s004 (2.66 MB TIF)
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